# Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)

> **NCT03297398** · PHASE2 · TERMINATED · sponsor: **OPKO Health, Inc.** · enrollment: 114 (actual)

## Conditions studied

- Benign Prostatic Hyperplasia

## Interventions

- **DRUG:** Group-1 (15mg, OPK-88004)
- **DRUG:** Group-2 (25 mg,OPK-88004)
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03297398
- **Lead sponsor:** OPKO Health, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-02-21
- **Primary completion:** 2019-04-18
- **Final completion:** 2019-06-10
- **Target enrollment:** 114 (ACTUAL)
- **Why stopped:** study terminated by sponsor decision
- **Last updated:** 2021-09-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03297398

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03297398, "Effects and Safety of OPK-88004 Doses in Men With Signs and Symptoms of Benign Prostatic Hyperplasia (BPH)". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03297398. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*